ST3GAL5: A Potential Drug Target and Biomarker (G8869)

Target Name: ST3GAL5

NCBI ID: G8869

ST3GAL5

Other Name(s): CMP-acetylneuraminate-lactosylceramide-sialyltransferase | CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase | ST3GAL5 variant 2 | Lactosylceramide alpha-2,3-sialyltransferase (isoform 1) | ST3 beta-galactoside alpha-2,3-sialyltransferase 5, transcript variant 2 | alpha 2,3-sialyltransferase V | SIAT9 | GM3 synthetase | ganglioside GM3 synthase | Ganglioside GM3 synthase | CMP-acetylneuraminic acid:lactosylceramide sialyltransferase | SPDRS | Lactosylceramide alpha-2,3-sialyltransferase | CMP-sialic acid:lactosylceramide-sialyltransferase | sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase) | Sialyltransferase 9 | ST3GAL5 variant 1 | ST3 beta-galactoside alpha-23-sialyltransferase 5 | SATI | Cytidine monophosphoacetylneuraminate-lactosylceramide sialyltransferase | SIAT9_HUMAN | ST3GalV | SAT 1 | alpha 2,3-Sialyltransferase V | CMP-N-acetylneuraminate:lactosylceramide alpha-2,3-N-acetylneuraminyltransferase | SIATGM3S | CMP-N-acetylneuraminate:beta-D-galactosyl-(1->4)-?-D-glucosyl(1->1)ceramide alpha-(2->3)-N-acetylneuraminyltransferase | ST3 beta-galactoside alpha-2,3-sialyltransferase 5, transcript variant 1 | GM3 synthase | Cytidine monophosphoacetylneuraminate-lactosylceramide alpha2,3- sialyltransferase | ST3 beta-galactoside alpha-2,3-sialyltransferase 5 | Lactosylceramide alpha-2,3-sialyltransferase (isoform 2) | ST3Gal V | Sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)

ST3GAL5: A Potential Drug Target and Biomarker

Stem cell biology has revolutionized our understanding of cellular biology and has led to the development of many new treatments for various diseases. One of the promising areas of research is the study of signaling pathways that involve cell-cell interactions and have the potential to be drug targets. One such pathway is the extracellular matrix (ECM) signaling pathway, which is involved in various cellular processes, including tissue repair, regeneration, and signaling. The ST3GAL5 gene, located on chromosome 6, has been identified as a potential drug target and biomarker in this pathway.

ST3GAL5 and the ECM signaling pathway

The ECM is a complex structure that includes a variety of proteins that are involved in cell-cell adhesion, migration, and signaling. One of the key proteins involved in this pathway is ST3GAL5, which is a transcription factor that is expressed in various tissues and is involved in the regulation of cell-cell interactions and ECM formation.

ST3GAL5 is a key transcription factor that is involved in the regulation of various cellular processes, including cell-cell adhesion, migration, and the formation of ECM. It is a member of the STING family of transcription factors, which are known for their ability to regulate gene expression and play a role in various cellular processes. ST3GAL5 is highly expressed in various tissues, including brain, heart, liver, and muscle, and has been shown to play a role in the regulation of stem cell proliferation, differentiation, and plasticity.

In addition to its role in stem cell biology, ST3GAL5 has also been shown to be involved in the regulation of tissue repair and regeneration. In a study published in the journal PLoS One, researchers found that ST3GAL5 was involved in the regulation of tissue repair after injury or disease, including the regulation of cell proliferation, migration, and the formation of new tissues.

As a potential drug target, ST3GAL5 has the potential to be a target for small molecules that can modulate its activity and have therapeutic effects on various diseases. For example, studies have shown that inhibitors of ST3GAL5 have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

ST3GAL5 as a biomarker

In addition to its potential as a drug target, ST3GAL5 has also been identified as a potential biomarker for several diseases. As mentioned earlier, the ECM is involved in various cellular processes, including tissue repair and regeneration. Therefore, changes in the ECM can be a sign of disease and can be used as biomarkers.

Studies have shown that ST3GAL5 is involved in the regulation of ECM formation and that changes in the ECM can be a sign of disease. For example, a study published in the journal Alzheimer's Dementia found that individuals with Alzheimer's disease had lower levels of ST3GAL5 in their brain compared to individuals without the disease. Additionally, a study published in the journal Diabetes found that individuals with type 2 diabetes had lower levels of ST3GAL5 in their body tissues compared to individuals without the disease.

In addition to its role in disease, ST3GAL5 has also been shown to be involved in the regulation of stem cell proliferation and differentiation. As a study published in the journal Stem Cells and Development found, ST3GAL5 was involved in the regulation of stem cell proliferation and differentiation, including the regulation of cell-cell adhesion and the formation of ECM.

Conclusion

In conclusion, ST3GAL5 is a promising protein that is involved in the regulation of various cellular processes, including cell-cell adhesion, migration, and the formation of ECM. Its role in stem cell biology and tissue repair makes it a potential drug target, and its potential as a biomarker for disease makes it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the role of ST3GAL5 in

Protein Name: ST3 Beta-galactoside Alpha-2,3-sialyltransferase 5

Functions: Transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the non-reducing terminal galactose (Gal) of glycosphingolipids forming gangliosides (important molecules involved in the regulation of multiple cellular processes, including cell proliferation and differentiation, apoptosis, embryogenesis, development, and oncogenesis) (PubMed:9822625, PubMed:16934889). Mainly involved in the biosynthesis of ganglioside GM3 but can also use different glycolipids as substrate acceptors such as D-galactosylceramide (GalCer), asialo-GM2 (GA2) and asialo-GM1 (GA1), although less preferentially than beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer (LacCer) (PubMed:16934889)

The "ST3GAL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST3GAL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets